Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer.

5-fluorouracil - Generic mfg.

Opdivo (nivolumab) - Ono Pharma, BMS

emavusertib (CA-4948) - Curis, Dr. Reddy’s

Herceptin (trastuzumab) - Roche

leucovorin calcium - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

https://www.asco.org/abstracts-presentations/255919

Patrick Grierson; Ramon Jin; Olivia Aranha; Moh'd M. Khushman; Kian-Huat Lim

Dec 2, 2025